PDS Biotechnology Corporation (NASDAQ: PDSB) Rose 19.29% From Its 52-Week Low; YTD Numbers Fall -14.06% – Here Are Some Things To Keep In Mind

During the recent session, PDS Biotechnology Corporation (NASDAQ:PDSB)’s traded shares were 7.24 million, with the beta value of the company hitting 1.45. At the last check today, the stock’s price was $1.40, reflecting an intraday gain of 4.54% or $0.06. The 52-week high for the PDSB share is $6.16, that puts it down -340.0 from that peak though still a striking 19.29% gain since the share price plummeted to a 52-week low of $1.13. The company’s market capitalization is $62.46M, and the average trade volume was 494.20K shares over the past three months.

PDS Biotechnology Corporation (PDSB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. PDSB has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.28.

PDS Biotechnology Corporation (NASDAQ:PDSB) trade information

PDS Biotechnology Corporation (PDSB) registered a 4.54% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.54% in intraday trading to $1.40, hitting a weekly high. The stock’s 5-day price performance is 5.32%, and it has moved by -12.45% in 30 days. Based on these gigs, the overall price performance for the year is -75.85%.

The consensus price target of analysts on Wall Street is $9, which implies an increase of 84.44% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9 and $9 respectively. As a result, PDSB is trading at a discount of -542.86% off the target high and -542.86% off the low.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 42.97%. While earnings are projected to return 20.14% in 2025, the next five years will return 3.39% per annum.

PDSB Dividends

PDS Biotechnology Corporation is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

PDS Biotechnology Corporation (NASDAQ:PDSB)’s Major holders

The next largest institutional holding, with 0.49 million shares, is of BLACKROCK INC.’s that is approximately 1.3987% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.43 million.

Also, the Mutual Funds coming in first place with the largest holdings of PDS Biotechnology Corporation (PDSB) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.02 shares. This amounts to just over 2.66 percent of the company’s overall shares, with a $1.44 million market value. The same data shows that the other fund manager holds slightly less at 456.79, or about 1.20% of the stock, which is worth about $0.65 million.